Government Regulation for more information. We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidates. Our clinical trials may be suspended at any time for a number of reasons. For example, we may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to the clinical trial patients. In addition, the FDA or other regulatory a...
Q2 FY2026 — expected 2026-08-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001193125-26-131928 | EDGAR | 80K words |
| 2025-04-01 | 2024-12-31 | 0001641172-25-001932 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0001493152-24-012357 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010332 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001493152-22-008080 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001493152-25-022304 | EDGAR | 28K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-024020 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010935 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001493152-24-045137 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001493152-24-031675 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001493152-24-018704 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001493152-23-040598 | EDGAR | — |
| 2023-08-16 | 2023-06-30 | 0001493152-23-029125 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001493152-23-016648 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001493152-22-031491 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001493152-22-022384 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001493152-22-013294 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001493152-26-013653 | EDGAR | 4K words |
| 2026-03-27 | 0001493152-26-013080 | EDGAR | — |
| 2026-03-23 | 0001493152-26-012058 | EDGAR | — |
| 2026-02-06 | 0001493152-26-005437 | EDGAR | — |
| 2026-01-02 | 0001493152-26-000113 | EDGAR | — |
| 2025-11-14 | 0001493152-25-023604 | EDGAR | — |
| 2025-11-13 | 0001493152-25-022325 | EDGAR | — |
| 2025-08-14 | 0001641172-25-024147 | EDGAR | — |
| 2025-06-25 | 0001641172-25-016512 | EDGAR | — |
| 2025-05-15 | 0001641172-25-010895 | EDGAR | — |
87 total filings indexed. 60 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001574094 |
| Ticker | RNXT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.renovorx.com |
| Listed | 2021-08-26 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report